Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension.
Journal: American journal of respiratory and critical care medicine
Published: August 08, 2025
Circulating biomarker results from a phase 2 study of seralutinib in pulmonary arterial hypertension.
Journal: American journal of respiratory and critical care medicine
Published: August 08, 2025
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
Journal: The Lancet. Respiratory medicine
Published: September 28, 2023
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply.
Journal: Alimentary pharmacology & therapeutics
Published: March 04, 2022
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis.
Journal: Alimentary pharmacology & therapeutics
Published: October 08, 2021
RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Journal: Gastroenterology
Published: July 19, 2018
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Journal: The New England journal of medicine
Published: May 05, 2016
Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis.
Journal: Alimentary pharmacology & therapeutics
Published: March 25, 2016
Myers-Briggs personality preferences may enhance physician leadership success in non-clinical jobs.
Journal: Physician executive
Published: June 28, 2013
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
Journal: Gut
Published: March 07, 2013
Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
Journal: The Journal of rheumatology
Published: July 17, 2012
Last Updated: 09/26/2026